Cytokinetics CYTK EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's EPS (basic)?
- Cytokinetics (CYTK) reported EPS (basic) of -$1.67 in Q1 2026.
- How has Cytokinetics's EPS (basic) changed year-over-year?
- Cytokinetics's EPS (basic) decreased by 22.8% year-over-year, from -$1.36 to -$1.67.
- What is the long-term trend for Cytokinetics's EPS (basic)?
- Over 4 years (2021 to 2025), Cytokinetics's EPS (basic) has grown at a 23.6% compound annual growth rate (CAGR), from -$2.80 to -$6.53.
- What does EPS (basic) mean?
- The portion of a company's profit allocated to each outstanding share of common stock.
- How do you interpret EPS (basic)?
- Higher values indicate better earnings performance per share, while negative values indicate a loss per share.
- How does EPS (basic) compare across companies?
- Standard equity valuation metric used by investors to compare profitability across companies.